Projects per year
Fingerprint
Dive into the research topics where Ulrich G. Steidl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting
9/1/21 → 8/31/22
Project: Research project
-
Contribution of macrophages in the HSC niche
Frenette, P. S., Steidl, U. G. & Will, B.
National Heart, Lung, and Blood Institute
4/1/21 → 2/28/23
Project: Research project
-
A Fluorescence-Based High-Throughput Platform for Glycotyping the Hematopoietic Cell Lineage
Buelow, H. E. & Steidl, U. G.
9/1/19 → 8/31/22
Project: Research project
-
STAT3 inhibition as a therapeutic strategy against MDS stem cells
Steidl, U. G., Verma, A. K., Steidl, U. G. & Verma, A. K.
National Heart, Lung, and Blood Institute
7/23/19 → 6/30/22
Project: Research project
-
STAT3 inhibition as a therapeutic strategy against MDS stem cells
7/23/19 → 6/30/22
Project: Research project
-
Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)
Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., Hong, D. S., Wang, J. S., Steidl, U., Walensky, L. D., Naik, G., Guerlavais, V., Vukovic, V., Annis, D. A., Aivado, M. & Meric-Bernstam, F., Jan 15 2022, In: Clinical Cancer Research. 28, 2, p. 429 1 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Posttranscriptional Arid3a deregulation in AMKL
Wheat, J. C. & Steidl, U., Feb 3 2022, In: Blood. 139, 5, p. 637-638 2 p.Research output: Contribution to journal › Editorial › peer-review
Open Access -
The DNA dioxygenase Tet1 regulates H3K27 modification and embryonic stem cell biology independent of its catalytic activity
Chrysanthou, S., Tang, Q., Lee, J., Taylor, S. J., Zhao, Y., Steidl, U., Zheng, D. & Dawlaty, M. M., Apr 8 2022, In: Nucleic acids research. 50, 6, p. 3169-3189 21 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Rahmani, N. E., Ramachandra, N., Sahu, S., Gitego, N., Lopez, A., Pradhan, K., Bhagat, T. D., Gordon-Mitchell, S., Pena, B. R., Kazemi, M., Rao, K., Giricz, O., Maqbool, S. B., Olea, R., Zhao, Y., Zhang, J., Dolatshad, H., Tittrea, V., Tatwavedi, D., Singh, S. & 10 others, , Sep 2021, In: Blood cancer journal. 11, 9, 157.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Jasra, S., Kazemi, M., Shah, N., Chen, J., Fehn, K., Wang, Y., Mantzaris, I., Kornblum, N., Sica, A., Bachier, L. M., Goldfinger, M., Gritsman, K., Braunschweig, I., Steidl, U., Shastri, A. & Verma, A., Dec 2021, In: Experimental Hematology and Oncology. 10, 1, 1.Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations